BL 1020

Drug Profile

BL 1020

Alternative Names: AN-168; BL-1020; CYP-1020; Perphenazine GABA ester; Perphenazine-4-aminobutyrate

Latest Information Update: 18 Mar 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bar-Ilan University; Tel Aviv University
  • Developer BioLineRx
  • Class Antipsychotics; Esters; Phenothiazines; Piperidines; Small molecules
  • Mechanism of Action Dopamine receptor antagonists; GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Schizoaffective disorder; Schizophrenia

Most Recent Events

  • 18 Mar 2014 Discontinued - Phase-II for Schizoaffective disorder in Israel (PO)
  • 18 Mar 2014 Discontinued - Phase-II for Schizoaffective disorder in Romania (PO)
  • 18 Mar 2014 Discontinued - Phase-II for Schizophrenia in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top